Short Report

Two polymorphisms in the epithelial cell-derived neutrophil-activating peptide (ENA-78) gene

Mahsa M. Amolia,b,*, Bagher Larijani a, Wendy Thomson b, William E.R. Ollier b and Miguel A. Gonzalez-Gay c

aEndocrinology and Metabolism Research Centre, Tehran University of Medical Sciences, Tehran, Iran
bCentre for Integrated Genomic Medical Research, Manchester University Medical School, Manchester, UK, USA
cDivisions of Rheumatology and Pediatrics Hospital Xeral-Calde, Lugo, Spain

Abstract. Increased expression of epithelial cell-derived neutrophil-activating peptide (ENA-78) has been reported in several immune and inflammatory conditions suggesting its role in inflammatory response. We have identified two single nucleotide polymorphisms in the promoter and exon 2 of the ENA-78 gene by scanning the full length gene using DHPLC DNA fragment analysis and DNA sequencing.

The polymorphism at position +398 (A/G from the first ATG codon) in exon 2 results in a synonymous substitution not resulting in an amino acid change. The promoter polymorphism was found at position −156 (C/G from the first ATG codon). An assay was designed for the detection of the polymorphisms using SNapshot ddNTP primer extension, followed by capillary electrophoresis (ABI 3100).

Allele and genotype frequencies for the promoter −156 polymorphism are presented for 107 healthy Spanish and 54 UK Caucasians. Frequencies for the exon 2 polymorphism are also presented for 63 UK Caucasians.

Keywords: ENA-78, polymorphism, biallelic

1. Introduction

Epithelial cell-derived neutrophil-activating peptide ENA-78 belongs to the CXC subfamily of chemokines and is expressed by epithelial cells after stimulation with pro-inflammatory cytokines such as IL-1B and TNFA inducing polymorphonuclear neutrophil (PMN) adhesiveness [1]. Zimmerman et al. have shown that ENA-78 is also released by stimulated endothelial cells in human lung and other tissues and can act in concert with IL-8 to induce neutrophil pro-adhesive activity [2]. ENA-78 biological activity appears to be similar to IL-8, however its synthesis and release by endothelial cells differs from IL-8, possibly due to different transcription regulation pathways. Higher levels of ENA-78 have been detected in chronic pancreatitis compared to normal and also it is raised in severe acute pancreatitis suggests involvement of this chemokine in the initiation and perpetuation of disease [3,4]. It has also been observed as being an important chemokine expressed in a number of inflammatory diseases such as Crohn’s disease, ulcerative colitis and Rheumatoid arthritis [5,6]. In diabetic patients an increased neutrophil activation is observed which is evidenced by augmented basal level of metabolic processes in unstimulated neutrophil, enhanced concentration of neu-
trophil elastase and increased activity of neutrophil alkaline phosphatase (ALP) [7]. Diabetic patients with microvascular complications have a higher neutrophil activity than patients without complications [8].

The ENA-78 gene has been mapped to chromosome 4q13-q21 in the same region as other CXC subfamily genes and consists of 4 exons and three introns, resembling the organisation of the IL-8 gene [9].

In order to identify polymorphisms in the ENA-78 gene, the full sequence of the gene was scanned using DHPLC (wave™ analysis) and two novel polymorphisms have been detected.

For mutation detection the full length sequence of the gene was examined as four separate segments and amplified using the primers shown in Table 1. PCR reactions containing 1x NH4 buffer (Bioline), 1.5 mM MgCl2, 0.2 mM dNTPs (Bioline), 5 pmol of each primer and 1 U Taq polymerase (Bioline) and 1 mM Betaine (Sigma). The same conditions were used for exon 2 polymorphism. Thermal cycling for the promoter polymorphism was as follows: 95°C for 2 min followed by 40 cycles each of 95°C for 45s, 59°C for 45s and 72°C for 45s and a final extension of 72°C for 2 min. A PCR product of 246 bp was visualised on a 3% agarose gel stained with ethidium bromide.

For the exon 2 polymorphism PCR was carried out by 95°C for 2 min followed by 40 cycles each of 95°C for 45s, 49°C for 45s and 72°C for 45s and a final extension of 72°C for 2 min. A PCR product of 312 bp was visualised on a 3% agarose gel.

The probes used for the single nucleotide extension in the primer extension kit were:

Promoter polymorphism:
- Promoter polymorphism: 5'-CAG ACA ATG GGA ACT GGT-3'
- Exon 2 polymorphism: 5'-ATC ATT TTG GGA TGA ACT CC-3'

After extension and purification, the product was electrophoresed on an 3100 ABI analyser and the results were analysed with Genescan software.

Genotype and allele frequencies for the −156 polymorphism are summarised in Table 2 for 107 Northern Spanish and 54 UK healthy Caucasoids. Frequencies for the +398 polymorphism are also given for a group of 63 healthy UK Caucasoids.
Table 2
Allele and Genotype frequencies of ENA-78 exon 2 promoter and exon 2 polymorphism

| Genotype | UK     | Spanish |
|----------|--------|---------|
| −156 G/C | N = 54 | N = 107 |
| G/G      | 34(63%)| 79(74%) |
| G/C      | 18(34%)| 25(23%) |
| C/C      | 2(3%)  | 3(3%)   |
| Allele   |        |         |
| G        | 86(80%)| 183(86%)|
| C        | 22(20%)| 31(14%) |
| Exon 2 A/G | N = 63 |         |
| G/G      | 20(32%)|         |
| G/A      | 38(60%)|         |
| A/A      | 5(7%)  |         |
| Allele   |        |         |
| G        | 78(62%)|         |
| A        | 48(38%)|         |

Both polymorphisms were found to conform to Hardy-Weinberg equilibrium, using Chi-square analysis (Statistical package Stata v6).

Although the polymorphism in exon 2 is a synonymous single nucleotide change (not changing conserved amino acids), −156 G/C polymorphism which is located in the promoter region can influence gene expression level. These polymorphisms may be useful in the study of the genetics of diabetes and its microvascular complications which chemokines and neutrophil activations play an important role. In vitro studies for functional relevance of the −156 G/C polymorphism on the expression of the gene is needed.

References

[1] A. Walz, R. Burgener, B. Car, M. Baggiolini, S.L. Kunkel and R.M. Strieter, Nucleotide Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8, J Exp Med. 174 (1991), 1355–1362.

[2] T. Imaizumi, K.H. Albertine, D.L. Jicha, T.M. McIntyre, S.M. Prescott and G.A. Zimmerman, Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion, Am J Respir Cell Mol Biol. 17 (1997), 181–192.

[3] L. Saurer, P. Reber, T. Schaffner, M.W. Buchler, C. Buri, A. Kappeler et al., Differential expression of chemokines in normal pancreas and in chronic pancreatitis, Gastroenterology. 118 (Feb. 2000) 356–367.

[4] S. Shokuhi, M. Bhatia, S. Christmas, R. Sutton, J.P. Neoptolemos and J. Slavin, Levels of the chemokines growth-related oncogene alpha and epithelial neutrophil-activating protein 78 are raised in patients with severe acute pancreatitis, Br J Surg. 89 (May. 2002) 566–572.

[5] A. Walz, P. Schmutz, C. Mueller and S. Schnyder-Candrian, Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease, J Leukoc Biol. 62 (1997), 6040–611.

[6] A.E. Koch, S.L. Kunkel, L.A. Harlow, D.D. Mazarakis, G.K. Haines, M.D. Burdick, R.M. Pope, A. Walz and R.M. Strieter, Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis, J Clin Invest. 94 (1994), 1012–1018.

[7] Y.A. Aleksandrovski, Molecular mechanisms of diabetic complications, Biochemistry (Mosc) 63 (1998), 1249–1257.

[8] A. Patel, S. Ratnachayavong, B.A. Milward and A.G. Domaine, Polymorphism of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications, Adv Exp Med Biol. 328 (1993), 325–332.

[9] M.S. Chang, J. McNinch, R. Basu and S. Simonet, Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene, J Biol Chem. 269 (1994), 25277–25282.